Sanitas AB - Notification on material event

On the review of Sanitas AB strategic options

The Management Board and major shareholders of Sanitas AB (“Sanitas” or the"Company") initiated a strategic review in April 2008, to consider various
strategic options available to the Company to enhance and realize shareholder
value. Merrill Lynch International acted as financial adviser to the Company in
the strategic review.  This review has concluded that the Company's stand-alone
operating plan represents the best way to enhance shareholder value for the
medium term. This conclusion was reached based on a thorough analysis of the
pharmaceutical industry, current macroeconomic conditions and available
strategic transaction alternatives. 

On the basis of the conclusions of the strategic review and taking into account
that Sanitas financial performance remains strong and the Company has a strong
balance sheet as well as attractive niche positions in its key markets and good
growth prospects, the Management Board of the Company on October 28, 2008
decided that the main focus of the Company in the medium term remains therefore
its pipeline of new products and further growth in its current markets. 

Jurist
Alina Nausedaite
+ 370 37 20 06 62